Piper Sandler Highlights Arrowhead Pharmaceuticals, Inc. (ARWR) Pipeline With Upcoming Phase III Hypertriglyceridemia Data

We recently compiled a list of the 15 High Growth Mid-Cap Stocks to Buy. Arrowhead Pharmaceuticals, Inc. is among the best high growth stocks. 

TheFly reported on January 13 that Piper Sandler lifted its price target on ARWR to $110 from $100, and reiterated an Overweight rating. The firm mentioned the new release of Redemplo for familial chylomicronemia syndrome, with more robust growth anticipated for FY27 and cautious sales projections for FY26. The analyst also voiced confidence regarding upcoming Phase III data in severe hypertriglyceridemia later in 2026, which would enable substantial label expansion.

Separately, on January 7, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced that China’s NMPA approved Redemplo (plozasiran) to lower triglycerides in adults with familial chylomicronemia syndrome. This decision is the drug’s third regulatory clearance after clearances in the US and Canada. Sanofi will offer Redemplo in Greater China as part of an ongoing regional partnership, extending the therapy’s global reach.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a U.S. biopharmaceutical company developing RNA interference (RNAi)-based medicines that silence disease-causing genes. It targets rare and serious diseases with innovative therapies, including its first FDA-approved drug, and advances a broad pipeline through internal programs and strategic partnerships.

While we acknowledge the potential of ARWR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.